AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

AngioDynamics shares are finally showing signs of positive momentum. Click for this ANGO stock update and see if it is the ...

AngioDynamics anticipates $336M-$341M FY 2027 net sales while targeting $13M-$16M adjusted EBITDA

Q4 FY 2026. Management view "We capped off a year of consistent execution across the business with a strong fourth quarter. Full-year ...
TCTMD

TCT 928: Suction Before Closure: Novel Use of AngioVac Thrombectomy of a Left Atrial Appendage Thrombus to Facilitate Watchman Implantation

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
TCTMD

TCT 173: Complications and Failure Modes of The Angiovac Thrombectomy System: Insight from MAUDE Database

TCT 176: Randomized comparison of intracoronary lithotripsy and rotational atherectomy for the treatment of severely calcified vessels – ROTA.shock trial Receive the the latest news, research, and ...
Nasdaq

AngioDynamics Receives FDA Breakthrough Device Designation for the AngioVac System for the Non-Surgical Removal of Right Heart Vegetation

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...